Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

🤖 Plain-English Summary

Abstract The global supply of COVID-19 vaccines remains limited. Immune markers were not correlated with asymptomatic infections at the 5% significance level.

🔑 Key Findings

• An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines.
• Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2.
• Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients.

🔗 Related Resources